Menu
Back to Journals » Journal of Blood Medicine » Volume 2
Emerging treatments for essential thrombocythemia
Authors Okoli, Harrison C
Published 2 December 2011 Volume 2011:2 Pages 151—159
DOI https://doi.org/10.2147/JBM.S19053
Review by Single anonymous peer review
Peer reviewer comments 5
Steven Okoli, Claire Harrison
Department of Haematology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK
Abstract: In 1934, Epstein and Goedel used the term hemorrhagic thrombocythemia to describe a disorder characterized by permanent elevation of a platelet count to more than three times normal, hyperplasia of megakaryocytes, and the tendency for venous thrombosis and spontaneous hemorrhage. Over the last 75 years, and particularly in the past 6 years, major progress has been made in our understanding of essential thrombocythemia (ET) and its pathogenesis with the identification of the highly prevalent JAK-2 V617F and other mutations. Current management of this condition is based upon historical data and with treatments that have not changed significantly for nearly two decades. This study discusses this and recent progress, highlighting exciting new data with old and new drugs, as well as which patients in particular should be evaluated for these new therapies.
Keywords: essential thrombocythemia, interferon, JAK inhibitor
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.